(London, UK) September 11, 2025. Naitive Technologies, a medical technology company developing AI-driven software to reimagine orthopedic care, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship product, OsteoSight. OsteoSight enables opportunistic assessment of bone mineral density (BMD) using standard X-rays acquired to investigate other clinical concerns, such as pain associated with arthritis or a fall.
Naitive® Receives FDA 510(k) Clearance for OsteoSight™, AI-Enabled Opportunistic Bone Health Assessment
3 min read Premium comments
OTWPRBoost
Osteoporosis, characterized by the progressive loss of BMD, impacts millions of Americans and costs healthcare systems billions each year. Yet, 70% of patients with low BMD are undiagnosed1 often until a fracture occurs. Earlier diagnosis drives earlier intervention, improving outcomes and reducing the condition’s impact2. OsteoSight is designed to enable orthopedic practices to take a proactive role in osteoporosis management, supporting earlier interventions, and new growth opportunities for practices.
The device earned designation as an FDA Breakthrough Device in 2023 and has been validated in peer-reviewed research3. Developed with a range of world-leading partners and front-line clinicians, OsteoSight addresses an urgent unmet clinical need, with a solution that fits seamlessly into the existing orthopedic workflow.
OsteoSight analyzes routine X-rays of the hip or pelvis in patients 50 years and older and opportunistically identifies cases at risk for low BMD. It then provides a notification in the form of a report to aid the interpreting physician and prompt a clinical assessment of bone health.
“The FDA’s clearance of OsteoSight technology represents a critical step forward in orthopedics. By utilizing X-rays that are already part of routine practice, this technology enables the orthopedic community to identify patients with poor bone health, who otherwise go unnoticed,” said Dr. Javad Parvizi, former President of the American Association of Hip and Knee Surgeons (AAHKS). “Having this insight at the point of care can help surgeons and practices intervene earlier, improve surgical planning, and ultimately enhance patient outcomes. This technology is truly unique and innovative.”
“We are proud that OsteoSight has received FDA 510(k) clearance,” said Dr. Will Briggs, CEO of Naitive. “It reflects the dedication of our team and validates the urgency of the problem we are solving. Millions of patients live with undetected osteoporosis, and orthopedic practices are uniquely positioned to change that. With this milestone, Naitive can now deliver real impact to orthopedic practices and their patients and lay the foundation for a broader platform in proactive bone health.”
With FDA clearance, Naitive is advancing commercial partnerships to bring OsteoSight into orthopedic practices across the US. The technology is the first step in building a comprehensive bone health platform designed to expand proactive care, improve patient outcomes, and create new growth opportunities for providers.
References
- https://link.springer.com/article/10.1007/s00198-025-07395-3
- https://jamanetwork.com/journals/jama/fullarticle/2829238
- https://link.springer.com/article/10.1007/s00198-025-07487-0
About Naitive Technologies
Naitive is a medical technology company developing AI-driven software to reimagine orthopedic care. We are dedicated to solving urgent challenges in musculoskeletal health by building intelligent, pathway-driven technologies that help orthopedic providers surface at-risk patients, convert them to treatment, and coordinate their care – ensuring that every high-risk patient is identified early, treated appropriately, and supported throughout their journey.
OsteoSight™, our flagship technology, enables opportunistic assessment of low bone mineral density (BMD) from routine X-rays, seamlessly embedding bone health into the orthopedic care pathway. By driving earlier intervention, enabling more informed surgical planning, and addressing the urgent need to reduce osteoporotic fractures, OsteoSight exemplifies our mission to redefine how care is delivered – making better outcomes and stronger health systems a reality.
Built on academic leadership from Oxford and Cambridge and in collaboration with world-leading healthcare systems, Naitive is powering the future of orthopedic care.
Discover more at naitive.com.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.